The effects of heparin and low molecular weight heparins on bone

Thrombosis Research

Volumn 122, Issue 3, 2008, Pages 293-298

  Rajgopal, Raghav ^a   Bear, MacKenzie ^a   Butcher, Martin K ^a   Shaughnessy, Stephen G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bone; Heparin; Low molecular weight heparin; Osteoporosis

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

BONE DENSITY; CLINICAL TRIAL; DRUG EFFECT; FRACTURE; HEALTH HAZARD; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BONE AND BONES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OSTEOPOROSIS;

EID: 45849107647     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.10.025     Document Type: Review

References (36)

1. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin H.L., Raschke R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 119 S1 (2001) S64-S94
2. Warkentin T.E., and Kelton J.G. Heparin-induced thrombocytopenia. Prog Hemost Thromb 10 (1991) 1-34
3. Rupp W.M., McCarthy H.B., Rohde T.D., Blackshear P.J., Goldenberg F.J., and Buchwald H. Risk of osteoporosis in patients treated with long-term intravenous heparin therapy. Curr Surg 39 6 (1982) 419-422
4. Monreal M., Olive A., Lafoz E., and Del Rio L. Heparins, coumarin, and bone density. Lancet 338 8768 (1991) 706
5. Murphy M.S., John P.R., Mayer A.D., Buckels J.A.C., and Kelly D.A. Heparin therapy and bone fractures. Lancet 340 8827 (1992) 1098
6. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168 4 (1993) 1265-1270
7. Barbour L.A., Kick S.D., Steiner J.F., LoVerde M.E., Heddleston L.N., Lear J.L., et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170 (1994) 862-869
8. Dahlman T.C., Sjoberg H.E., and Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 170 (1994) 1315-1320
9. Monreal M., Lafoz E., Olive A., del Rio L., and Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71 (1994) 7-11
10. Shefras J., and Farquharson R.G. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 65 (1996) 171-174
11. Douketis J.D., Ginsberg J.S., Burrows R.F., Duku E.K., Webber C.E., and Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 75 (1996) 254-257
12. Pettila V., Kaaja R., Leinonen P., Ekblad U., Kataja M., and Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 96 (1999) 275-282
13. Schulman S., and Hellgren-Wangdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost 87 (2002) 180-181
14. Pettila V., Leinonen P., Markkola A., Hiilesmaa V., and Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87 (2002) 182-196
15. Young E., Wells P., Holloway S., Weitz J., and Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71 (1994) 300-304
16. Groce III J.B. Treatment of deep vein thrombosis using low-molecular-weight heparins. Am J Manag Care 7 17 (2001) S510-S515 [discussion S515-23]
17. Bates S.M. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 108 (2002) 97-106
18. Chan W.S., Anand S., and Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160 (2000) 191-196
19. Ginsberg J.S., Greer I., and Hirsh J. Use of antithrombotic agents during pregnancy. Chest 119 S1 (2001) S122-S131
20. Muir J.M., Andrew M., Hirsh J., Weitz J.I., Young E., Deschamps P., et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88 4 (1996) 1314-1320
21. Shaughnessy S.G., Hirsh J., Bhandari M., Muir J.M., Young E., and Weitz J.I. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 93 4 (1999) 1231-1236
22. Nelson-Piercy C., Letsky E.A., and de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176 (1997) 1062-1068
23. Casele H.L., and Laifer S.A. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 9 (2000) 122-125
24. Wawrzynska L., Tomkowski W.Z., Przedlacki J., Hajduk B., and Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 33 2 (2003) 64-67
25. Carlin A.J., Farquharson R.G., Quenby S.M., Topping J., and Fraser W.D. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Human Reprod 19 5 (2004) 1211-1214
26. Muir J.M., Hirsh J., Weitz J.I., Andrew M., Young E., and Shaughnessy S.G. A histomorphometric comparison of the effects of heparin and low-molecular weight heparin on cancellous bone in rats. Blood 89 9 (1997) 3236-3242
27. Shaughnessy S.G., Young E., Deschamps P., and Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86 4 (1995) 1368-1373
28. Bauer K.A. New anticoagulants: anti IIa vs anti Xa- is one better?. J Thromb Thrombolysis 21 1 (2006) 67-72
29. Handschin A.E., Trentz O.A., Hoerstrup S.P., Kock H.J., Wanner G.A., and Trentz O. Br J Surg 92 (2005) 177-183
30. Osip S.L., Butcher M., Young E., Yang L., and Shaughnessy S.G. Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro. Thromb Haemost 92 (2004) 803-810
31. Bhandari M., Hirsh J., Weitz J.I., Young E., Venner T.J., and Shaughnessy S.G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 80 (1998) 413-417
32. Matzsch T., Bergqvist D., Hedner U., Nilsson B., and Ostergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 63 (1990) 505-509
33. Monreal M., Vinas L., Monreal L., Lavin S., Lafoz E., and Angles A.M. Heparin-related osteoporosis in rats. A comparative study between unfractionated heparin and low-molecular-weight heparin. Haemostasis 20 (1990) 204-207
34. Nishiyama M., Itoh F., and Ujiie A. Low-molecular-weight heparin (Dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol 74 (1997) 59-68
35. Folwarczna J., Janiec W., Barej M., Cegiela U., Pytlik M., and Kaczmarczyk-Sedlak I. Effects of nadroparin on bone histomorphometric parameters in rats. Pol J Pharmacol 56 3 (2004) 337-343
36. Folwarczna J., Janiec W., Gawor M., Pytlik M., Kaczmarczyk-Sedlak I., and Nowinska B. Effects of enoxaparin on histomorphometric parameters of bones in rats. Pol J Pharmacol 56 4 (2004) 451-457